

Effects of resistance exercise on the cognitive function through modulation of

AMPK, PGC-1, BDNF protein expression in PD mice

Sang-Hoon Kim · Seung-Soo Baek

1 Department of Sport & Health Care, College of Art & Culture, Sangmyung University



INTROTUCTION

Degenerative brain disease is the fourth most common cause of death in Korea. Among them, the incidence of Parkinson's disease (PD) increases about 2.5 times per year, which is a serious problem in an aging society. Although the cause of PD is not clear, PD is characterized by decreased motor function and cognitive impairment due to dopamine dysfunction and reduced neurogenesis. Drugs used clinically have serious side effects, so it needs to find an effective and safe method of treatment from a pathophysiological point of view.

In degenerative brain disease, peroxisome proliferator-activated receptor gamma co-activator 1alpha (PGC-1q) is suggested as a cause of cognitive impairment, whereas PGC-1a induces the expression of fibronectin type III domain-containing protein 5 (FNDC5) and brain-derived neurotrophic factor (BDNF). Currently, exercise therapy is drawing attention as a treatment method for PD. The benefits of exercise therapy are that it promotes body function recovery and improves cognitive function. Best of all, it is safe from side effects. However, muscle strength is required to prevent deterioration of motor function in PD patients, but studies on the effects of resistance exercise are insufficient compared to aerobic exercise studies. In this study, we investigated the effect of resistance exercise on AMP-activated protein kinase(AMPK), Peroxisome proliferatoractivated receptor gamma coactivator 1-alpha (PGC-1q), brain-derived neurotrophic factor(BDNF) protein expression in the PD mouse.

MATERIALS AND METHODS

The experimental groups were divided into 4 groups: control group, PD-induction group, PDinduction and resistance exercise group, PD-induction and levodopa treated group.

Control Parkinson's disease(PD)
PD - resistance exercise PD - drug (levodopa)

The PD mouse model was induced by an intraperitoneal injection of MPTP for twice a week(10 times).



For the resistance exercise group was performed for 5 weeks, and levodopa treated group received levodopa at dose of 20mg/kg for 5 weeks

Set	1 – 2 weeks	3 – 4 weeks	4 – 5 weeks
Warm-up	Conducted twice without weight		
1 - 2	30% of the weight of the mouse	40% of the weight of the mouse	50% of the weight of the mouse
3 - 4	37.5% of the weight of the mouse	47.5% of the weight of the mouse	57.5% of the weight of the mouse
5 - 6	45% of the weight of the mouse	55% of the weight of the mouse	65% of the weight of the mouse
7 - 8	52.5% of the weight of the mouse	62.5% of the weight of the mouse	72.5% of the weight of the mouse
9 - 10	60% of the weight of the mouse	70% of the weight of the mouse	82% of the weight of the mouse

The Morris water maze test and step down avoidance test were used to evaluate cognitive function



5-bromo-2'-deoxyuridine(BrdU) immunohistochemistry was used to assess neurogenesis. Western blotting was also performed to assess levels of AMPK, PGC-1a, BDNF. RESULTS: Decreased spatial memory with reduced AMPK and PGC1a, BDNF protein expressions were found in the PD mice.

